THE RISKS AND ADVANTAGES OF ANTI-DIABETES THERAPY IN THE POSITIVE COVID-19 PATIENT

Ferrara F; De Rosa F; Pelliccia C; La Porta R; Vitiello A

doi:10.22270/ujpr.v5i3.419

Ferrara F Usl Umbria 1, Perugia, Italy
De Rosa F Regione Campania, Naples, Italy
Pelliccia C Usl Umbria 2, Terni, Italy
La Porta R Asur Marche, Macerata, Italy
Vitiello A 1Usl Umbria 1, Perugia, Italy

10.22270/ujpr.v5i3.419

Keywords:

COVID-19, diabetes, hyperglycemia, inflammatory, immunomodulants, Sars-Cov-2

Abstract

The new Sars-Cov-2 (COVID-19) is causing thousands of deaths worldwide and has caused a global pandemic, one of the biggest health challenges ever faced in history. in the most severe cases, Sars-Cov-2 infection can cause fatal lung injuries. In this context, it is essential to recognise effective therapeutic agents against the virus. There are currently no direct and effective vaccines and antivirals available. People with pre-existing conditions, such as diabetes, and with chronic drug therapies in place may represent complex patients difficult to manage clinically during COVID-19 infection and at high risk of major complications. The regulation of blood glucose and the adoption of appropriate measures are critical aspects to consider for the diabetic patient in this pandemic period, especially in the patient with ongoing infection. In this article we describe the current evidence in the literature on the possible risks of side effects caused by taking antidiabetic drugs in the COVID-19 patient and the data on extra homeostasis glycemic activity useful to fight viral infection.